The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ORGS | -55.46% | -99.25% | -62.39% | +37% |
| S&P | +13.95% | +78.35% | +12.25% | +527% |
Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing, and provision of technologies, and services in the cell and gene therapy industry. It operates through the Morgenesis and Therapies segments. The Morgenesis segment refers to the POCare services. The Therapies segment is involved in therapeutic development operations. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD.
No news articles found for Orgenesis.
| Q3 2024 | YOY Change | |
|---|---|---|
| Revenue | $347.00K | 0.0% |
| Gross Profit | -$628.00K | 0.0% |
| Gross Margin | -180.98% | 0.0% |
| Market Cap | $21.28M | 0.0% |
| Net Income | -$9,266.00K | 0.0% |
| EBITDA | -$7,083.00K | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2024 | YOY Change | |
|---|---|---|
| Net Cash | $1.12M | 0.0% |
| Accounts Receivable | $161.00K | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2024 | YOY Change | |
|---|---|---|
| Long Term Debt | $10.10M | 0.0% |
| Short Term Debt | $7.19M | 0.0% |
| Q3 2024 | YOY Change | |
|---|---|---|
| Return On Assets | -145.76% | 0.0% |
| Return On Invested Capital | 498.92% | 0.0% |
| Q3 2024 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4,688.00K | 0.0% |
| Operating Free Cash Flow | -$4,630.00K | 0.0% |
| Metric | Q1 2024 | Q2 2024 | Q3 2024 | YoY Change |
|---|---|---|---|---|
| Price to Book | -1.25 | -0.74 | -1.35 | - |
| Price to Sales | 51.55 | 35.22 | 23.39 | - |
| Price to Tangible Book Value | -8.86 | -5.39 | -0.82 | - |
| Enterprise Value to EBITDA | -6.44 | -10.38 | -5.25 | - |
| Total Debt | $27.83M | $13.02M | $17.30M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
